BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC.
暂无分享,去创建一个
R. Fanin | M. Krampera | E. Calistri | A. Ambrosetti | F. Marchi | M. Medeot | M. Tiribelli | M. Bonifacio | A. Bonalumi | E. Maino | G. Semenzato | G. Binotto | L. Scaffidi | Luca Frison | M. Narbergoj